ASBP

$0.88

Market ClosedAs of Mar 17, 8:00 PM UTC

Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$0.88
Potential Upside
5%
Whystock Fair Value$0.92
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, ...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.40M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.89
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.14

Recent News

TipRanks
Feb 4, 2026

Aspire Biopharma’s Buzz Bomb partners with Blue Shark Beverages

Aspire Biopharma (ASBP) wholly owned subsidiary, Buzz Bomb Caffeine Company, announced a strategic brand management and distribution agreement with Blue Shark Beverages. Effective February 1, the relationship is expected to drive the retail expansion of BUZZ BOMB, a proprietary 50mg sublingual caffeine stick pack in four flavors, across key Southern California markets. The rollout will debut in Palm Springs and surrounding cities in the Coachella Valley, followed by a phased expansion into the L

BEARISH
Negative press. News cycle fixated on risk factors or misses.
TipRanks
Jan 28, 2026

Aspire files patent application for clopidogrel sublingual powder formulation

Aspire Biopharma (ASBP) announced the filing of a new provisional patent application with the United States Patent and Trademark Office. The application, titled “A Sublingual Powder Formulation of Clopidogrel and Methods of Use Thereof,” covers the first-ever sublingual formulation of clopidogrel, the active pharmaceutical ingredient in the widely prescribed blood thinner Plavix. This development represents a series of sublingual-based therapeutic alternatives the Company intends to commercializ

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Associated Press Finance
Jan 14, 2026

BC-Most Active Stocks

Nu Holdings Ltd. 35,303,567 16.69

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Jul 25, 2025

Aspire Biopharma’s BUZZ BOMB Shows Promising Initial Feedback

Aspire Biopharma Holdings Inc. (NASDAQ:ASBP) is one of the best penny stocks under $1 to buy now. On July 9, Aspire Biopharma Holdings announced positive initial consumer feedback for its new sublingual pre-workout supplement, called BUZZ BOMB. The product features 50mg of caffeine and provides sustained energy and mental focus to athletes and fitness enthusiasts, […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
TipRanks
May 29, 2025

Aspire Biopharma provides development update on BUZZ BOMB supplement

Aspire Biopharma (ASBP) announced the brand name BUZZ BOMB and anticipated market launch for its novel sublingual pre-workout supplement. BUZZ BOMB features 50mg of caffeine and is designed to support sustained energy and mental focus, helping athletes and fitness enthusiasts maximize their performance potential. Aspire has commenced initial production of BUZZ BOMB, its single serving pre-workout caffeine supplement utilizing Aspire’s patent-pending and proprietary sublingual delivery technology

BEARISH
Negative press. News cycle fixated on risk factors or misses.